Vous êtes redirigé vers un site externe.

GSK n'accepte aucune responsabilité suite à l'utilisation des sites internet tiers, y compris en ce qui concerne leur contenu.

Poursuivre

Retour

Nucala - Respiratoire
(Mepolizumab)

Indication:
Nucala est indiqué chez l'adulte, l’adolescent et l’enfant âgé de 6 ans et plus, en traitement additionnel, dans l’asthme sévère réfractaire à éosinophiles.

Nucala (mepolizumab)

The only anti-IL-5 to demonstrate powerful and lasting reduction in exacerbations and OCS dose for up to 4.8 years in patients with severe eosinophilic asthma. 123 Now available with the power to choose: at home or in hospital administration. 5 Transform the lives of your patients with the powerful and lasting protection of Nucala. 1

hyperlink,10000

Starter kit Nucala Seringue

• Une brochure d'instructions
• Une introduction à l'asthme grave
• Lien vers la video

NP-BE-MPL-LBND-190015

Starter kit Nucala siringe

Item added

Starter kit Nucala Seringue

• Une brochure d'instructions
• Une introduction à l'asthme grave
• Lien vers la video

NP-BE-MPL-LBND-190015

Starter kit Nucala siringe

Item added

Starter kit Nucala Stylo

• Une brochure d'instructions
• Une introduction à l'asthme grave
• Lien vers la video

NP-BE-MPL-LBND-190008

Starter kit Nucala Pen

Item added

Dispositif de Nucala Seringue

NP-BE-MPL-IMU-190002

 

 



Dispositif de Nucala PEN

Item added

Dispositif de Nucala Stylo

NP-BE-MPL-IMU-190003

 

Dispositif de Nucala PEN

Item added

Abbreviations:

ED: emergency department ; ICS: inhaled corticosteroid ; IL-5: interleukin-5 ; OCS: oral corticosteroid

*Annualised rate at Week 24: 0.51/year vs. 1.21/year; p<0.0001 (additional study endpoint) 2
**Annualised rate at Week 24; 0.03/year vs. 0.10/year; p=0.031 (additional study endpoint)
2
At Week 24 when added to high-dose ICS and additional maintenance treatment; Nucala n=69, placebo n=66 (secondary study endpoint). 3
††Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks, regardless of weight and available in lyophilised powder. 5

References:

  1. Khurana S; Clinical Therapeutics;2019;41;2041-2056.e5
  2. Chupp GL et al. Lancet Respir Med 2017; 5:390-400.
  3. Bel EH et al. N Engl J Med 2014; 371: 1189-1197.
  4. Khatri S et al. J Allergy Clin Immunol 2019; 143:1742-1751.e7 (including supplementary materials).
  5. Nucala SmPC.
  6. de Carvalho-Pinto RM, et al. Respir Med. 2012;106:47–56.
  7. Albers FC, et al. J Asthma. 2018;55:152–160.

Nucala is registered trademark of the GlaxoSmithKline Group of Companies

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 5

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, pre-filled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6-11 years is 40mg SC regardless of weight and available in lyophilised powder. 5

Nucala est une marque déposée de GlaxoSmithKline